SHORT ANSWER
FDA reviewed xcelpeptides.com in October 2024 and quoted product-page copy for seven peptides describing weight loss, blood-sugar control, cardiovascular benefit, and muscle growth. The letter states that “for research use only” and “not intended for human use” labeling was noted and that the website evidence still established intended human drug use. Phrasing benefits as happening in “test subjects” did not change that reading.
This material is general educational information as of the “last reviewed” date. It is not legal advice and may not reflect later developments or facts specific to your business. Links are provided so readers can inspect the primary or official sources.
01 / WHAT FDA REVIEWED
One website, one month, seven products
The letter is dated December 10, 2024, and is addressed to Xcel Research LLC in Sheridan, Wyoming. It opens by stating that FDA reviewed the website at xcelpeptides.com in October 2024 and observed products offered for sale in the United States.
The products named are “RETA” (retatrutide), “CagriLean” (cagrilintide and semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (semaglutide), “SURVODUTIDE,” and “SERMORELIN.” FDA states in the first paragraph that these are unapproved new drugs introduced into interstate commerce, and then spends the body of the letter showing how it reached that conclusion.
The letter describes what FDA observed on one site during one review window. It is not a statute, a rule for every seller, or a prediction about any other storefront.
02 / THE DISCLAIMER PARAGRAPH
FDA quotes the labeling before setting it aside
The second paragraph is the one most sellers care about. FDA writes: “Despite statements on your product labeling marketing your products, ‘FOR RESEARCH USE ONLY’ and ‘NOT INTENDED FOR HUMAN USE,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”
Two things are worth noticing. FDA read the disclaimer and quoted it verbatim, so the argument is not that the labeling was missing. And the sentence turns on the phrase “evidence obtained from your website,” which the rest of the letter then lays out product by product.
03 / THE QUOTED CLAIMS
Product copy, quoted back with the URL
For each product FDA cites the exact webpage and reproduces the seller’s own sentences. The claims fall into a few repeating patterns.
- Weight and appetite: retatrutide “exhibits potential for weight management by regulating appetite and metabolism in research test subjects”; semaglutide “promotes satiety and reduces food intake, leading to decreased body weight and fat mass.”
- Blood sugar and insulin: cagrilintide “may help stabilize blood sugar levels” for “research test subjects with conditions such as diabetes or insulin resistance”; survodutide’s “ability to improve blood sugar control in research lab subjects” is called “crucial for managing conditions like diabetes.”
- Cardiovascular and disease framing: retatrutide is said to lower blood pressure, “thus reducing the risk of cardiovascular diseases such as hypertension and atherosclerosis”; mazdutide “exhibits cardioprotective effects”; semaglutide is described as offering “potential benefits in neurodegenerative diseases such as Alzheimer’s disease.”
- Muscle and metabolism: sermorelin’s “primary benefits observed in test subjects” include “enhanced muscle growth and repair” and “improved metabolism and fat loss.”
- Drug-class language: survodutide “belongs to a class of drugs known as dual agonists,” in the seller’s own words.
04 / THE “TEST SUBJECTS” FRAMING
Substituting the noun did not change the claim
Nearly every quoted sentence attaches its benefit to “research subjects,” “test subjects,” or “research lab subjects” rather than to people. FDA reproduced those sentences as its evidence of intended human use without commenting on the substitution.
The claims themselves describe effects in a body: appetite, insulin sensitivity, blood pressure, endothelial function, muscle repair, and named human diseases. A sentence that says a compound helps “test subjects with conditions such as diabetes” still describes treating diabetes. The letter treats the word choice as irrelevant to what the sentence communicates.
Swapping “patients” for “subjects” leaves the intended-use signal intact. The question a reviewer asks is what effect the sentence describes and in what kind of body, not which noun carries it.
05 / THE LEGAL MECHANISM
Drug by intended use, new drug by lack of recognition, violation by lack of approval
The letter’s chain of reasoning is short and cites three provisions of the Federal Food, Drug, and Cosmetic Act.
First, the products are drugs under section 201(g)(1), 21 U.S.C. 321(g)(1), “because they are intended to prevent, treat, or cure disease conditions and/or affect the structure or function of the body.” Intended use is the hinge. The regulation that explains how intended use is established, 21 CFR 201.128, points to labeling, advertising, written statements, and the circumstances of distribution; the Xcel letter applies that logic through the website copy without citing the regulation by number.
Second, the products are “new drugs” under section 201(p), 21 U.S.C. 321(p), because they are “not generally recognized as safe and effective for the above referenced uses.”
Third, new drugs may not be introduced into interstate commerce without an approved application, per sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d). FDA states that no approved application is in effect for any of the seven products.
06 / WHAT FDA DEMANDED
Fifteen working days and a written response
The conclusion states that the letter “is not intended to be an all-inclusive statement of violations” and that the company is responsible for investigating causes and preventing recurrence. It warns that failure to address the matter “may result in legal action including, without limitation, seizure and injunction.”
FDA asks for a written response within fifteen working days describing the specific steps taken, an explanation of each step meant to prevent recurrence, and copies of related documentation. If the company disagrees, it is invited to include its reasoning and supporting information. If corrections cannot be completed in fifteen working days, the response should state the reason and the expected completion date.
07 / WHAT TO REVIEW
Read your own product pages the way this letter reads them
The letter’s method is simple: open each product page, copy the sentences that describe an effect, and list them under the product name. A storefront operator can run the same exercise before anyone else does.
- Any sentence that names an outcome in a body: weight, appetite, glucose, blood pressure, cholesterol, muscle, cognition, or sleep.
- Any sentence that names a human disease or condition, including inside a phrase like “subjects with conditions such as.”
- “Research subjects,” “test subjects,” and “lab subjects” used as a stand-in for people; the effect described is what matters.
- Language borrowed from drug marketing: “class of drugs,” “clinical trials,” “dual agonist,” “cardioprotective.”
- Headings such as “Health Benefits” or “Benefits of” above a benefits list.
- Where the research-use-only line sits relative to these sentences; proximity does not neutralize them, but a reviewer will note the contrast.
QUESTIONS
Related questions
Did the Xcel letter say the disclaimer was missing or badly placed?
No. FDA quoted the “FOR RESEARCH USE ONLY” and “NOT INTENDED FOR HUMAN USE” labeling directly. The letter’s point is that the website evidence established intended human use regardless of that labeling.
Does describing effects in “research subjects” instead of people avoid the problem?
The letter suggests not. Every quoted claim used “subjects” phrasing, and FDA reproduced those sentences as evidence of intended human drug use. The effect described, not the noun, is what the letter treats as the claim.
Can RUO Clear tell me whether my site would receive a letter like this?
No. A scan reports what was observed, which source each finding maps to, and what was not examined. It is issue-spotting and education, not a legal determination or a prediction of what a regulator will do.
SOURCES
Sources cited
Each source is listed with its class so government authority, agency guidance, enforcement examples, and private policy are never blended into one rule.
The letter walked through in this guide. Quotes seven product pages from xcelpeptides.com reviewed in October 2024.
The two definitions the letter relies on: a product is a drug by its intended use, and a new drug when not generally recognized as safe and effective for that use.
Explains how intended use is established: labeling, advertising, written statements, and circumstances of distribution. Not cited by number in the Xcel letter, but the logic the letter applies.